Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1998-8-20
|
| pubmed:abstractText |
A randomized, open-label prospective study was conducted with recipients of primary cadaveric liver allografts to characterize the disposition and immunodynamics of basiliximab, an interleukin-2 receptor, alpha-chain chimeric monoclonal antibody for immunoprophylaxis of acute rejection. Patients received a total intravenous dose of 40 mg basiliximab in addition to baseline dual immunosuppression consisting of cyclosporine (INN, ciclosporin) and steroids. The central distribution volume was 5.6 +/- 1.7 L with a steady-state volume of 7.5 +/- 2.5 L. It was cleared slowly with a total body clearance of 75 +/- 24 ml/hr and an elimination half-life of 4.1 +/- 2.1 days. Basiliximab was measurable in drained ascites fluid, and clearance by this route was an average of 20% of total clearance. Total body clearance correlated positively with volume of postoperative blood loss (r = 0.5253, p = 0.0101), suggesting that bleeding may represent an additional route of drug removal. A threshold relation was observed between serum concentration of basiliximab and CD25 expression on T lymphocytes whereby complete saturation of interleukin-2 receptor alpha-chain was maintained as long as serum concentrations exceeded 0.1 microgram/ml. The duration of receptor saturation was 23 +/- 7 days after transplantation (range, 13 to 41 days).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/basiliximab
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0009-9236
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
64
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
66-72
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9695721-Adolescent,
pubmed-meshheading:9695721-Adult,
pubmed-meshheading:9695721-Antibodies, Monoclonal,
pubmed-meshheading:9695721-Cyclosporine,
pubmed-meshheading:9695721-Demography,
pubmed-meshheading:9695721-Dose-Response Relationship, Drug,
pubmed-meshheading:9695721-Female,
pubmed-meshheading:9695721-Humans,
pubmed-meshheading:9695721-Immunosuppressive Agents,
pubmed-meshheading:9695721-Infusions, Intravenous,
pubmed-meshheading:9695721-Liver Transplantation,
pubmed-meshheading:9695721-Male,
pubmed-meshheading:9695721-Metabolic Clearance Rate,
pubmed-meshheading:9695721-Middle Aged,
pubmed-meshheading:9695721-Prospective Studies,
pubmed-meshheading:9695721-Receptors, Interleukin-2,
pubmed-meshheading:9695721-Recombinant Fusion Proteins,
pubmed-meshheading:9695721-Transplantation, Homologous
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Disposition and immunodynamics of basiliximab in liver allograft recipients.
|
| pubmed:affiliation |
Novartis Pharma AG, Basel, Switzerland.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|